Skip to content

CONMED CNMD Additional Paid-In Capital

Additional Paid-In Capital at other companies

Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$10.2B+1.1%
Medtronic logo
MedtronicMDT
$20.93B+0.4%
IAR
Integra LifeSciencesIART
$1.34B+1.3%
Solventum logo
SolventumSOLV
$3.9B+3.0%
Enovis logo
EnovisENOV
$3.06B+1.2%
Globus Medical logo
Globus MedicalGMED
$3.21B+5.0%

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.07B-35.6%
Enterprise value$1.89B-24.5%
P/E19.4×+5.5×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's additional paid-in capital?
CONMED (CNMD) reported additional paid-in capital of $508.49M in Q1 2026.
How has CONMED's additional paid-in capital changed year-over-year?
CONMED's additional paid-in capital increased by 4.0% year-over-year, from $489.1M to $508.49M.
What is the long-term trend for CONMED's additional paid-in capital?
Over 5 years (2020 to 2025), CONMED's additional paid-in capital has grown at a 5.6% compound annual growth rate (CAGR), from $382.63M to $503.2M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.